Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Index Can Predict Survival in Patients with MM
Clin Lymphoma Myeloma Leuk; ePub 2017 Sep 19; Ely, et al
Plasma cell proliferation index (PCPI) can help predict overall survival in people with newly diagnosed multiple myeloma, according to a study involving 151 individuals. Furthermore, it enables broader use of multiple myeloma cell proliferation for categorizing risk. Investigators grouped participants based on low (n=87) and high (n=64) myeloma cell proliferation. Using a plasma cell-specific biomarker, they evaluated how well multiplex immunohistochemistry calculated a PCPI. Among the results:
- Median overall survival was not reached in the low PCPI group, vs ~79 months in the high PCPI group.
- Only high-risk cytogenetics, ISS stage >I, and PCPI >5 independently impacted overall survival.
- 36% of patients with low risk disease were re-identified as high risk by PCPI.
Ely S, Forsberg P, Ouansafi I, et al. Cellular proliferation by multiplex immunohistochemistry identifies high risk multiple myeloma in newly diagnosed, treatment naïve patients. [Published online ahead of print September 19, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.09.010.
This Week's Must Reads
Must Reads in Multiple Myeloma
Study supports long-term survival in multiple myeloma subgroup, Usmani SZ et al. Blood Cancer J. 2018 Nov 23;8(12):123
Haploidentical allo-HCT possible even in relapsed myeloma, Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.
Osteoporosis tied to mortality risk in women with multiple myeloma, Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):597-602.e1.
Simulated model could target myeloma treatment, Ubels J et al. Nat Commun. 2018 Jul 27. doi: 10.1038/s41467-018-05348-5.
Researchers propose frailty index for older patients with multiple myeloma, Mian HS et al. JCO Clin Cancer Inform. 2018 Jul 25. doi: 10.1200/CCI.18.00043.